ReviewOncology letters2018
Research progress on common adverse events caused by targeted therapy for colorectal cancer.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Long intergenic non-coding RNA 00511 (LINC00511) genetic variations and haplotype implication for colorectal cancer susceptibility and prognosis.Scientific reports · 2025Article
- Differential expression of PLAC1 and Netrin-1 in liver metastasis of colorectal cancer and its predictive value.BMC gastroenterology · 2023Article
- Nursing care and management of adverse events for patients with BRAFSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Pan-integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling.American journal of cancer research · 2023Article
- Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer.Journal of the advanced practitioner in oncology · 2022Review
- Anticolon Cancer Targets and Molecular Mechanisms of Tao-He-Cheng-Qi Formula.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Identifying Novel Actionable Targets in Colon Cancer.Biomedicines · 2021Review
- Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China.BMC cancer · 2021Article
- Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.Cancer medicine · 2021Article
- Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.Clinical journal of gastroenterology · 2020Article
- Review
- Antitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models.Future science OA · 2020Article
- Research Progress on Chemical Constituents and Anticancer Pharmacological Activities ofBioMed research international · 2020Review
- Bee Collected Pollen and Bee Bread: Bioactive Constituents and Health Benefits.Antioxidants (Basel, Switzerland) · 2019Review
- [Palliative surgery of malignant small bowel obstruction after colorectal cancer].Wiener medizinische Wochenschrift (1946) · 2019Review
- The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.Investigational new drugs · 2019Article
- Potential proapoptotic phytochemical agents for the treatment and prevention of colorectal cancer.Oncology letters · 2019Review
- Synthesis of Chalcone Derivatives: Inducing Apoptosis of HepG2 CellsFrontiers in pharmacology · 2019Article
- Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As targeted drug therapy is increasingly applied in the treatment of colon cancer, understanding and managing the adverse reactions of patients is becoming increasingly important. The present review examines the mechanisms of and adverse reactions to the most commonly used targeted drugs for colon cancer, and discusses methods of coping with these adverse reactions. Approved targeted drugs for metastatic colon cancer include monoclonal antibodies targeting vascular endothelial growth factor (VEGF), including bevacizumab, ziv-aflibercept and regorafenib, and monoclonal antibodies targeting epithelial growth factor receptor (EGFR), including cetuximab and panitumumab. The present review assesses the major adverse effects of these drugs and methods of dealing with reactions to them. VEGF inhibitors primarily result in cardiovascular and kidney problems. Meanwhile, EGFR receptor inhibitors are frequently reported to cause rashes, diarrhea and hypertension, and are reviewed from the point of view of resulting electrolyte disturbances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.